Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy

Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.

Detalles Bibliográficos
Autores principales: Meucci, Elisa, Radice, Anna, Fassio, Filippo, Iorno, Maria Loredana Chiara, Macchia, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529882/
https://www.ncbi.nlm.nih.gov/pubmed/34721849
http://dx.doi.org/10.1002/ccr3.4935
_version_ 1784586556892250112
author Meucci, Elisa
Radice, Anna
Fassio, Filippo
Iorno, Maria Loredana Chiara
Macchia, Donatella
author_facet Meucci, Elisa
Radice, Anna
Fassio, Filippo
Iorno, Maria Loredana Chiara
Macchia, Donatella
author_sort Meucci, Elisa
collection PubMed
description Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.
format Online
Article
Text
id pubmed-8529882
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85298822021-10-28 Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy Meucci, Elisa Radice, Anna Fassio, Filippo Iorno, Maria Loredana Chiara Macchia, Donatella Clin Case Rep Case Report Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients. John Wiley and Sons Inc. 2021-10-21 /pmc/articles/PMC8529882/ /pubmed/34721849 http://dx.doi.org/10.1002/ccr3.4935 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Meucci, Elisa
Radice, Anna
Fassio, Filippo
Iorno, Maria Loredana Chiara
Macchia, Donatella
Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_full Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_fullStr Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_full_unstemmed Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_short Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
title_sort omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529882/
https://www.ncbi.nlm.nih.gov/pubmed/34721849
http://dx.doi.org/10.1002/ccr3.4935
work_keys_str_mv AT meuccielisa omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy
AT radiceanna omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy
AT fassiofilippo omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy
AT iornomarialoredanachiara omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy
AT macchiadonatella omalizumabforpreventionofanaphylacticepisodesinapatientwithseveremosquitoallergy

Ejemplares similares